Drugs / folitropin alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04899193 | May 2021 → May 2022 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | folitropin alfa | “Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or...” NCT04899193 ↗ |
| Known as | Gonal-f | “Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or...” NCT04899193 ↗ |
| Modality | Protein / enzyme biologic | “900 IU of recombinant human follicle-stimulating hormone (r-hFSH)” NCT04899193 ↗ |
| Route | Subcutaneous | “as subcutaneous injection” NCT04899193 ↗ |